Keith P. Klugman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Keith P. Klugman has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Avril D Wasas
2 shared publicationsRobin E Huebner
2 shared publicationsAlan Kimura
Wyeth Lederle Vaccines and Pediatrics, West Henrietta, New York
1 shared publicationAvril D. Wasas
MRCISAIMRIWITS Pneumococcal Diseases Research Unit, Johannesburg, South Africa
1 shared publicationCarol A. Widdowson
Medical Research Council, South African Institute for Medical Research, WITS Pneumococcal Diseases Research Unit, Johannesburg, South Africa
1 shared publicationCharles Feldman
Johannesburg Hospital and the University of the Witwatersrand
1 shared publication
Latest Publications
- 1 July 2003
- Vol. 93 (7) , 505-8
Antibiotic prescribing practices for common childhood illnesses in South Africa.
- 1 July 2003
- Vol. 93 (7) , 505-8
Antibiotic prescribing practices for common childhood illnesses in South Africa.
- 1 April 2003
- Vol. 93 (4) , 283
Correlation between erythromycin and azithromycin resistance in Streptococcus pneumoniae.
- 1 April 2003
- Vol. 93 (4) , 283
Correlation between erythromycin and azithromycin resistance in Streptococcus pneumoniae.
- Open Access
- 1 August 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (2) , 626
Levofloxacin-Resistant Pneumococcus
Sir—Wortmann and Bennett [1] report the isolation of Streptococcus pneumoniae from the blood and CSF of a patient who had received 4 days of levofloxacin therapy (500 mg orally once daily). In order to assess the likelihood that this might occur in the future, it is important to know the levofloxacin MIC of the pathogen. Pharmocodynamic principles would suggest that strains with levofloxacin MICs of 4–8 µg/mL would be unlikely to be eradicated by the dosage of levofloxacin they used. The authors described “a zone of inhibition of zero” determined by the E-test (AB Biodisk, Piscataway, NJ). The E-test gives a quantitative MIC and is not read in terms of a zone diameter. Could the authors clarify the MIC of the E-test? If indeed there was no inhibition at all around the E-test, are the authors suggesting that the MIC of this strain is ≥32µg/mL, which is the appropriate interpretation of a levofloxacin E-test with no zone of inhibition?
- 1 August 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (2) , 626
Open AccessLevofloxacin-Resistant Pneumococcus
Sir—Wortmann and Bennett [1] report the isolation of Streptococcus pneumoniae from the blood and CSF of a patient who had received 4 days of levofloxacin therapy (500 mg orally once daily). In order to assess the likelihood that this might occur in the future, it is important to know the levofloxacin MIC of the pathogen. Pharmocodynamic principles would suggest that strains with levofloxacin MICs of 4–8 µg/mL would be unlikely to be eradicated by the dosage of levofloxacin they used. The authors described “a zone of inhibition of zero” determined by the E-test (AB Biodisk, Piscataway, NJ). The E-test gives a quantitative MIC and is not read in terms of a zone diameter. Could the authors clarify the MIC of the E-test? If indeed there was no inhibition at all around the E-test, are the authors suggesting that the MIC of this strain is ≥32µg/mL, which is the appropriate interpretation of a levofloxacin E-test with no zone of inhibition?
- 1 February 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (2) , 393-395
Acquisition of Chloramphenicol Resistance by the Linearization and Integration of the Entire Staphylococcal Plasmid pC194 into the Chromosome of Streptococcus pneumoniae
Chloramphenicol resistance in Streptococcus pneumoniaewas associated with cat, which has 100% identity withcat pC194 from Staphylococcus aureus. Inverse PCR with primers specific for pC194 confirmed that in some isolates the entire staphylococcal plasmid was present in the S. pneumoniae chromosome, with linearization having occurred between cat pC194 and the origin of replication.
- 1 February 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (2) , 393-395
Acquisition of Chloramphenicol Resistance by the Linearization and Integration of the Entire Staphylococcal Plasmid pC194 into the Chromosome of Streptococcus pneumoniae
Chloramphenicol resistance in Streptococcus pneumoniaewas associated with cat, which has 100% identity withcat pC194 from Staphylococcus aureus. Inverse PCR with primers specific for pC194 confirmed that in some isolates the entire staphylococcal plasmid was present in the S. pneumoniae chromosome, with linearization having occurred between cat pC194 and the origin of replication.
- 1 October 1999
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 180 (4) , 1171-1176
Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine
The safety, immunogenicity, and impact on carriage of a nonvalent pneumococcal vaccine given at ages 6, 10, and 14 weeks were examined in a double-blind, randomized, placebo-controlled trial in 500 infants in Soweto, South Africa. No serious local or systemic side effects were recorded. Significant antibody responses to all pneumococcal serotypes were observed 4 weeks after the third dose. Haemophilus influenzae type b polyribosylribitol phosphate (geometric mean titer, 11.62 μg/mL) and diphtheria (1.39 IU/mL) antibodies were significantly higher in children receiving pneumococcal conjugate, compared with placebo recipients (4.58 μg/mL and 0.98 IU/mL, respectively). Nasopharyngeal carriage of vaccine serotypes decreased in vaccinees at age 9 months (18% vs. 36%), whereas carriage of nonvaccine serotypes increased (36% vs. 25%). Carriage of penicillin-resistant pneumococci (21% vs. 41%) and cotrimoxazole-resistant pneumococci (23% vs. 35%) were significantly reduced 9 months after vaccination, compared with controls.
- 1 October 1999
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 180 (4) , 1171-1176
Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine
The safety, immunogenicity, and impact on carriage of a nonvalent pneumococcal vaccine given at ages 6, 10, and 14 weeks were examined in a double-blind, randomized, placebo-controlled trial in 500 infants in Soweto, South Africa. No serious local or systemic side effects were recorded. Significant antibody responses to all pneumococcal serotypes were observed 4 weeks after the third dose. Haemophilus influenzae type b polyribosylribitol phosphate (geometric mean titer, 11.62 μg/mL) and diphtheria (1.39 IU/mL) antibodies were significantly higher in children receiving pneumococcal conjugate, compared with placebo recipients (4.58 μg/mL and 0.98 IU/mL, respectively). Nasopharyngeal carriage of vaccine serotypes decreased in vaccinees at age 9 months (18% vs. 36%), whereas carriage of nonvaccine serotypes increased (36% vs. 25%). Carriage of penicillin-resistant pneumococci (21% vs. 41%) and cotrimoxazole-resistant pneumococci (23% vs. 35%) were significantly reduced 9 months after vaccination, compared with controls.
- 1 September 1999
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 13 (3) , 637-646
EMERGENCE OF DRUG RESISTANCE: Impact on Bacterial Meningitis
- 1 September 1999
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 13 (3) , 637-646
EMERGENCE OF DRUG RESISTANCE: Impact on Bacterial Meningitis
- 1 January 1999
- Published by Springer Nature in Drugs
- Vol. 58 (1) , 1-4
Penicillin- and Cephalosporin-Resistant Streptococcus Pneumoniae
The global emergence of pneumococci resistant to antimicrobial therapy has led to dilemmas in the management of pneumococcal infections. The principles of pharmacodynamics predict that penicillin and...
- 1 January 1999
- Published by Springer Nature in Drugs
- Vol. 58 (1) , 1-4
Penicillin- and Cephalosporin-Resistant Streptococcus Pneumoniae
The global emergence of pneumococci resistant to antimicrobial therapy has led to dilemmas in the management of pneumococcal infections. The principles of pharmacodynamics predict that penicillin and...
- Open Access
- 1 December 1998
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 4 (4) , 517-520
International Editors: Emerging Infectious Diseases—South Africa
Volume 4, Number 4—December 1998 - Emerging Infectious Disease journal - CDC
- 1 December 1998
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 4 (4) , 517-520
Open AccessInternational Editors: Emerging Infectious Diseases—South Africa
Volume 4, Number 4—December 1998 - Emerging Infectious Disease journal - CDC